摘要
目的:考察X射线损伤修复交叉互补基因1(XRCC1)Arg399Gln(G→A)多态性对晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及生存期的影响。方法:选取2013年1月-2015年1月海南省人民医院晚期胃癌患者52例,予奥沙利铂+氟尿嘧啶联合化疗,每3周为1个周期,均治疗3个周期以上。采用聚合酶链反应-连接酶检测反应法测定患者的基因型,比较不同基因型患者的疾病控制率和无进展生存期。结果:52例晚期胃癌患者中,XRCC1 GG基因型28例(53.8%)、GA基因型21例(40.4%)、AA基因型3例(5.8%),各基因型频率均符合Hardy-Weinberg平衡(P>0.05)。52例患者的疾病控制率为76.9%,其中GG基因型患者的疾病控制率(92.9%)显著高于GA+AA基因型(58.3%),差异有统计学意义(P<0.05);52例患者的平均无进展生存期为(7.1±1.2)个月,其中GG基因型患者的无进展生存期[(8.6±0.8)个月]显著长于GG+GA基因型[(5.9±0.7)个月],差异有统计学意义(P<0.05)。结论:XRCC1多态性与晚期胃癌患者奥沙利铂+氟尿嘧啶化疗疗效及无进展生存期有关,且XRCC1 GG基因型患者对化疗药物更敏感;该基因可能成为该类方案化疗疗效及生存期的预测标志物。
OBJECTIVE: To investigate the effect of X-ray repair cross complementing gene (XRCC1) Arg399Gln (C→A) polymorphism on efficacy of oxaliplatin+fluorouracil chemotherapy and survival time of advanced gastric cancer patients. METHODS: Totally 52 cases of advanced gastric cancer were selected from Hainan Provincial People's Hospital during Jan. 2013-Jan. 2015. They were given oxaliplatin+fluorouracil chemotherapy, for 3 courses (a treatment course lasted for 3 weeks). The genotypes of patients were detected by PCR-LDR. Disease control rate and progression free survival were compared among different geno- types. RESULTS: Among 52 cases of advanced gastric cancer, there were 28 cases of XRCC1 GG genotype (53.8%), 21 cases of GA genotype (40.4%), 3 cases of AA genotype (5.8%), frequencies of which were all in line with Hardy-Weinberg balance (P〉 0.05). Disease control rates of 52 cases were 76.9%, among which disease control rate (92.9%) of GG genotype was significantly higher than that of GA+AA genotype (58.3%), with statistical significance (P〈0.05). The average progression free survival of 52 cases was (7.1±1.2) months, among which progression free survival of GG genotype [ (8.6 ± 0.8) months] was significantly longer than that of GG+GA genotype [(5.9 ± 0.7)months], with statistical significance (P〈0.05). CONCLUSIONS: XRCC1 polymor- phism is correlated with efficacy of oxaliplatin+fluorouracil chemotherapy and progression free survival, and XRCC1 GG genotype is more sensitive to chemotherapy drugs. XRCC1 gene can be regarded as predictive indicator for therapeutic efficacy of chemothera- py and survival.
出处
《中国药房》
CAS
北大核心
2017年第14期1873-1876,共4页
China Pharmacy
基金
海南省医学普通科研课题(No.琼卫2012PT-17)
关键词
XRCC1
基因多态性
晚期胃癌
奥沙利铂
氟尿嘧啶
化疗疗效
无进展生存期
XRCC1
Gene polymorphism
Advanced gastric cancer
Oxaliplatin
Fluorouracil
Efficacy of chemotherapy
Progression free survival